Clinical Trial Update: A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating IBI362 for metabolic dysfunction-associated steatohepatitis (MASH), currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis

Drugs mentioned

• IBI362

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Status: RECRUITING